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Glucocorticoid Dosages and Acute- Phase Reactant Levels 
at Giant Cell Arteritis Flare in a Randomized Trial of 
Tocilizumab
John H. Stone,1 Katie Tuckwell,2 Sophie Dimonaco,3 Micki Klearman,2 Martin Aringer,4 Daniel Blockmans,5  
Elisabeth Brouwer,6 Maria C. Cid,7 Bhaskar Dasgupta,8 Juergen Rech,9 Carlo Salvarani,10  
Hendrik Schulze-Koops,11 Georg Schett,9 Robert Spiera,12 Sebastian H. Unizony,1 and Neil Collinson3
Objective. This study was undertaken to evaluate glucocorticoid dosages and serologic findings in patients with 
giant cell arteritis (GCA) flares.
Methods. Patients with GCA were randomly assigned to receive double- blind dosing with either subcutane-
ous tocilizumab (TCZ) 162 mg weekly plus 26- week prednisone taper (TCZ- QW + Pred- 26), every- other- week TCZ 
plus 26- week prednisone taper (TCZ- Q2W + Pred- 26), placebo plus 26- week prednisone taper (PBO + Pred- 26), or 
placebo plus 52- week prednisone taper (PBO + Pred- 52). Outcome measures were prednisone dosage, C- reactive 
protein (CRP) level, and erythrocyte sedimentation rate (ESR) at the time of flare.
Results. One hundred patients received TCZ- QW + Pred- 26, 49 received TCZ- Q2W + Pred- 26, 50 received PBO 
+ Pred- 26, and 51 received PBO + Pred- 52. Of the 149 TCZ- treated patients, 36 (24%) experienced flare, 23 (64%) 
of whom were still receiving prednisone (median dosage 2.0 mg/day). Among 101 PBO + Pred–treated patients, 59 
(58%) experienced flare, 45 (76%) of whom were receiving prednisone (median dosage 5.0 mg/day). Many flares 
occurred while patients were taking >10 mg/day prednisone: 9 (25%) in the TCZ groups and 13 (22%) in the placebo 
groups. Thirty- three flares (92%) in TCZ- treated groups and 20 (34%) in PBO + Pred–treated groups occurred with 
normal CRP levels. More than half of the PBO + Pred–treated patients had elevated CRP levels without flares. Bene-
fits of the TCZ and prednisone combination over prednisone alone for remission induction were apparent by 8 weeks.
Conclusion. Most GCA flares occurred while patients were still receiving prednisone. Acute- phase reactant levels 
were not reliable indicators of flare in patients treated with TCZ plus prednisone or with prednisone alone. The addi-
tion of TCZ to prednisone facilitates earlier GCA control.
INTRODUCTION
Giant cell arteritis (GCA) is a vasculitis of large- and medium- 
sized arteries that affects people ≥50 years old (1). Upon being 
diagnosed as having GCA, patients are treated immediately with 
high dosages of glucocorticoids to reduce the risk of vision loss 
and large vessel complications. Long- term glucocorticoid treat-
ment has traditionally been required to control symptoms and pre-
vent relapse in GCA patients (2), but flares frequently occur (3–5). 
Although GCA is the most common primary form of systemic vas-
culitis in Western countries, there are few data from randomized 
clinical trials regarding prednisone dosages at disease flares, 
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 particularly for patients treated with prednisone for 1 year—a 
course that approximates the standard of care for many clinicians. 
Additionally, the usefulness of acute- phase reactants (APRs) in 
the clinical assessment of GCA flares has been poorly studied in 
patients treated with prednisone alone or with tocilizumab (TCZ). 
Moreover, no randomized clinical trials have been conducted in 
which clinicians and patients were blinded with regard to pred-
nisone dosages and APR levels. TCZ, a humanized monoclonal 
antibody against the interleukin- 6 (IL- 6) receptor α, inhibits IL- 6–
mediated signaling and inflammatory pathways (6,7).
In the Giant Cell Arteritis Clinical Research Study (GiACTA), 
a randomized, double- blind, placebo (PBO)–controlled phase 
III study of patients with GCA, TCZ was superior to PBO in 
the achievement of sustained remission at 1 year (8). TCZ was 
approved for the treatment of patients with GCA in 2017. Blocking 
IL- 6 signaling with TCZ reduces levels of APRs such as C- reactive 
protein (CRP) and decreases the erythrocyte sedimentation rate 
(ESR) (7). Consequently, measuring APR levels to quantify sys-
temic inflammation is believed to have limited value in the clinical 
assessment of disease flares in patients with GCA treated with 
TCZ (9). GiACTA was the first randomized clinical trial in any dis-
ease (to our knowledge) to include a blinded, variable- dosage 
prednisone taper. Once patients reduced their daily prednisone 
dosage, according to protocol, to <20 mg/day, patients and 
physician- investigators were blinded with regard to glucocorticoid 
dosages unless a flare occurred. Disease flares were assessed 
largely on a clinical basis, irrespective of APR levels, because 
investigators were blinded with regard to CRP levels, and initially 
only the laboratory assessor was aware of ESR results.
The design of the GiACTA trial permits a unique opportunity 
to study prednisone dosages and laboratory features associated 
with disease flares in GCA patients treated with prednisone alone 
and those treated with TCZ plus prednisone. These trial data 
therefore provide guidance for clinical decision- making within the 
new and traditional treatment landscapes for GCA.
PATIENTS AND METHODS
Ethics board approval and informed consent. This 
trial was approved by institutional review boards and/or ethics 
committees at the appropriate institutions and was conducted 
in accordance with the Guidelines for Good Clinical Practice and 
the Declaration of Helsinki. All patients provided written informed 
consent.
Patients and study design. The patient eligibility criteria 
and study design for the GiACTA trial (ClinicalTrials.gov identifier: 
NCT01791153) have previously been published (10). Patients were 
randomly assigned 2:1:1:1 to 4 groups to receive treatment with 
weekly subcutaneous TCZ 162 mg plus a 26- week prednisone 
taper (TCZ- QW + Pred- 26), every- other- week subcutaneous TCZ 
162 mg plus a 26- week prednisone taper (TCZ- Q2W + Pred- 26), 
subcutaneous placebo plus a 26- week prednisone taper (PBO + 
Pred- 26), or subcutaneous placebo plus a 52- week prednisone 
taper (PBO + Pred- 52) (8). Randomization was stratified by base-
line prednisone dosage (≤30 mg/day or >30 mg/day). During the 
study, prednisone was tapered in a double- blind, protocol- defined 
manner (11). Prednisone was initially administered on an open- 
label basis at dosages of >20 mg/day and tapered according to 
weekly, protocol- defined decrements. Patients and investigators 
were blinded with regard to prednisone dosages of ≤20 mg/day.
To maintain rigorous blinding of investigators given the antic-
ipated normalization of APR levels with IL- 6 receptor blockade, a 
separate laboratory assessor was assigned to monitor laboratory 
parameters (including ESR) independently of the blinded inves-
tigator/efficacy assessor, who assessed the patient’s GCA and 
managed the prednisone taper. All investigators were blinded with 
regard to CRP level. The laboratory assessor was informed of ESR 
values, but the efficacy assessor was informed only whether the 
ESR was higher or lower than 30 mm/hour under strict protocol 
guidelines to ensure patient safety while preserving the blind (8).
Definition of GCA flares. GCA flare was determined by the 
investigator and defined as the recurrence of signs or symptoms 
of GCA or an ESR of ≥30 mm/hour attributed by the investigator to 
GCA even in the absence of any other overt clinical manifestations 
of active disease. The definition of disease flare included the need 
for an increase in the prednisone dosage at the time of the clinical 
event. The symptoms and signs of flare were categorized as fol-
lows: GCA signs and symptoms (new- onset localized  headache, 
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scalp tenderness, temporal artery tenderness or decreased pul-
sation, ischemia- related vision loss, and otherwise unexplained 
mouth or jaw pain on mastication) only, polymyalgia rheumatica 
(PMR) symptoms only, fever (≥38°C) only, visual symptoms (unilat-
eral and bilateral blindness, ischemic optic neuropathy, amaurosis 
fugax, blurred vision, and diplopia) only, elevated ESR (≥30 mm/
hour) attributed to active GCA only, and multiple symptoms (e.g., 
the occurrence of GCA and PMR symptoms together).
Study analysis. Assessments were performed at each 
study visit to determine whether a patient’s disease was fully con-
trolled and the patient could safely continue the prednisone taper. 
Remission or flare was determined by the investigator at each 
study visit. CRP normalization was not included in the definition of 
remission for this analysis, and, as noted, the investigators were 
blinded with regard to CRP level. Prednisone dosages and APR 
values at disease flare were evaluated at the time of first flare. 
CRP levels and ESR values were examined before flare, at the 
time of flare, and in the absence of clinical signs or symptoms of 
flare. If the ESR at the time of flare was unavailable, the last ESR 
value preceding the flare was used. Remission before baseline 
was determined by the investigator at each site. Many patients 
had achieved disease control before the baseline visit because 
of glucocorticoid use during the 6- week screening period. The 
proportions of patients achieving sustained remission, time to 
first flare, and cumulative prednisone duration and exposure were 
analyzed according to the patients’ baseline prednisone dosages 
(≤30 mg/day or >30 mg/day).
Statistical analysis. TCZ and PBO treatment groups were 
compared using the Cochran- Mantel- Haenszel test with adjust-
ment for the stratification factor of starting prednisone dosage 
(≤30 mg/day or >30 mg/day) for analysis of the proportions of 
patients in sustained remission and using a Cox proportional haz-
ards model with adjustment for the starting prednisone dosage 
for time to first flare. The secondary end point of remission rates 
over time and subgroup analyses by starting prednisone dosage 
and disease onset were prespecified. All other analyses were per-
formed post hoc and are exploratory, with no adjustment for Type I 
error control; therefore, we performed a limited number of statisti-
cal comparisons for these analyses. Hazard ratios (HRs) and 99% 
confidence intervals (99% CIs) were calculated. 
RESULTS
Baseline characteristics of patients in the GiACTA trial have 
been reported (8). Briefly, 251 patients were randomly assigned 
to receive TCZ- QW + Pred- 26 (n = 100), TCZ- Q2W + Pred- 26 
(n = 50), PBO + Pred- 26 (n = 50), or PBO + Pred- 52 (n = 51). 
The intent- to- treat and safety populations included 250 patients, 
because 1 patient assigned to the TCZ- Q2W + Pred- 26 group did 
not receive the study drug.
Flares. Among the 250 patients included in this analy-
sis, 95 (38%) experienced disease flares following a period of 
remission during the first 52 weeks of the study. Of these 95 
flares, 13 (13.7%) were characterized by symptoms consid-
ered typical of GCA only and 13 (13.7%) by PMR symptoms 
only. No flares following remission were characterized by visual 
symptoms alone, and none were based on the presence of 
fever alone. Clinical features at disease flare were not char-
acterized in additional detail. Nine flares (9.5%) were based 
only on increased ESR attributed to GCA in the absence of an 
alternative explanation. Only 1 patient in the TCZ- QW + Pred- 
26 group was reported to have a flare after remission without 
symptoms of flare or an ESR of ≥30 mm/hour (Table  1). All 
flares responded to increased glucocorticoid dosages.
Prednisone dosages at flare. The median prednisone 
dosage at the time of disease flare was 2.0 mg/day (range 
0.0–25.0) for the combined TCZ groups and 5.0 mg/day (0.0–
30.0) for the combined PBO groups. Of the 149 patients in 
the combined TCZ groups, 36 (24%) experienced GCA flares 
(Table 1); 23 of these 36 flares (63.9%) occurred while patients 
were still receiving prednisone (8 [22.2%] at a dosage of 1–5 
mg/day), and 13 (36.1%) occurred after discontinuation of the 
prednisone taper. Of the 101 patients in the combined PBO 
groups, 59 (58%) experienced GCA flares; 45 of these (76.3%) 
occurred while patients were still receiving prednisone, and 
14 (23.7%) occurred after discontinuation of the prednisone 
taper. Of the 50 patients who received PBO + Pred- 26, 9 of 
the 34 reported flares (26.4%) occurred at prednisone dosages 
of 1–5 mg/day. In contrast, two- thirds of the flares (17 of 25; 
68%) in the 51 patients in the PBO + Pred- 52 group occurred 
at prednisone dosages of >5–20 mg/day. Substantial numbers 
of disease flares occurred while patients were receiving >10 
mg/day prednisone, accounting for 9 (25%) of the flares in the 
TCZ groups and 13 (22.0%) in the PBO groups. No patients 
experienced flares while receiving prednisone dosages of >30 
mg/day, and only 3 patients experienced flares while receiving 
dosages of >20–30 mg/day.
Among patients randomly assigned to receive PBO + Pred, 
13 (38.2%) of the disease flares in the PBO + Pred- 26 group 
became manifest only after patients had tapered to a prednisone 
dosage of 0 mg/day (Table 1). In contrast, only 1 (4.0%) of the 
disease flares in the PBO + Pred- 52 group was diagnosed in 
a patient receiving a prednisone dosage of 0 mg/day; the rest 
of the flares in this group became clinically manifest before the 
patients tapered to 0 mg/day prednisone.
Relationships between APR level, disease activity, 
and flare. Flare with normal APR levels. Median CRP and ESR 
levels preceding GCA flare were lower in the TCZ groups than 
in the PBO groups (Table 1). This was expected based on the 
 biology of IL- 6 receptor blockade and its downstream effects on 
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Table 1. Prednisone dosages and acute- phase reactant levels at time of GCA flare*
Assessment at time of GCA flare
PBO +  
Pred- 26 
(n = 50)
PBO +  
Pred- 52 
(n = 51)
TCZ- QW + 
Pred- 26 
(n = 100)
TCZ- Q2W + 
Pred- 26 
(n = 49)
Flare experienced after remission 34 (68.0) 25 (49.0) 23 (23.0) 13 (26.5)
Signs and symptoms experienced  
at time of flare†
GCA signs and symptoms only‡ 2 (5.9) 1 (4.0) 5 (21.7) 5 (38.5)
PMR symptoms only 2 (5.9) 2 (8.0) 6 (26.1) 3 (23.1)
Fever (≥38°C) only 0 0 0 0
Visual symptoms only§ 0 0 0 0
Elevated ESR (≥30 mm/hour) only 6 (17.6) 2 (8.0) 1 (4.3) 0
Multiple symptoms 24 (70.6) 20 (80.0) 10 (43.5) 5 (38.5)
No symptoms of flare 0 0 1 (4.3) 0
Receiving steroids at time of  
first flare†¶
21 (61.8) 24 (96) 17 (73.9) 6 (46.2)
Prednisone dosage at flare, median 
(range) mg/day 
2.5 (0.0–30.0) 8.0 (0.0–20.0) 7.0 (0.0–25.0) 0.0 (0.0–12.5)
First flare experienced while  
receiving prednisone, by  
dosage in mg/day†
0 13 (38.2) 1 (4.0) 6 (26.1) 7 (53.8)
1–5 9 (26.5) 7 (28.0) 5 (21.7) 3 (23.1)
>5–10 5 (14.7) 11 (44.0) 4 (17.4) 2 (15.4)
>10–20 6 (17.6) 6 (24.0) 6 (26.1) 1 (7.7)
>20–30 1 (2.9) 0 2 (8.7) 0
>30–40 0 0 0 0
>50–60 0 0 0 0
>60 0 0 0 0
CRP level preceding flare,  
median (range) mg/liter#
23.1 (1.4–119.0) 17.3 (0.2–122.0) 0.4 (0.2–93.2) 1.0 (0.2–18.1)
Presence of elevated CRP  
at time of flare†#
22 (65) 17 (68) 1 (4) 2 (15)
Presence of elevated CRP  
without flare#
26 (52.0) 31 (60.8) 5 (5.0) 3 (6.1)
ESR preceding flare, median  
(range) mm/hour**
51.0 (8.0–140.0) 39.0 (4.0–138.0) 5.0 (0.0–80.0) 5.0 (1.0–43.0)
Presence of elevated ESR at  
time of flare†**
27 (79) 14 (56) 1 (4) 3 (23)
Presence of elevated ESR without flare 31 (62.0) 28 (54.9) 2 (2.0) 3 (6.1)
Presence of elevated CRP  
and ESR without flare
20 (40.0) 20 (39.2) 2 (2.0) 1 (2.0)
* Except where indicated otherwise, values are the number (%) of patients. GCA = giant cell arteritis; PBO + Pred- 26 = placebo 
plus 26- week prednisone taper; PBO + Pred- 52 = placebo plus 52- week prednisone taper; TCZ- QW + Pred- 26 = tocilizumab once 
weekly plus 26- week prednisone taper; TCZ- Q2W + Pred- 26 = tocilizumab once every 2 weeks plus 26- week prednisone taper; 
PMR = polymyalgia rheumatica; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein. 
† Values are the number (%) of patients in the corresponding treatment group who experienced flare following remission. 
‡ Includes new- onset localized headache, scalp tenderness, temporal artery tenderness or decreased pulsation, ischemia- 
related vision loss, and otherwise unexplained mouth or jaw pain on mastication. 
§ Includes unilateral and bilateral blindness, ischemic optic neuropathy, amaurosis fugax, blurred vision, and diplopia. 
¶ Includes prednisone and all other steroids. 
# Normal ≤10 mg/liter. 
** Normal <30 mm/hour. 
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Figure 1. Disease control during the first 52 weeks of treatment in all patients in the intent- to- treat population (A), and in patients with newly 
diagnosed (B) and relapsing (C) giant cell arteritis. Prespecified exploratory analysis of remission rates over time is shown. Remission was 
defined as absence of flare and did not include C- reactive protein level in the definition. Patients who withdrew from the study or received 
escape therapy were excluded from that point. Patients with missing information on remission status were considered not in remission for that 
time point only. Responders (patients in remission) were analyzed; therefore, values at week 52 are slightly higher than the highest values for 
sustained remission, which accounts for patients not adhering to the protocol- defined tapering regimen as nonresponders. PBO + Pred- 26 = 
placebo plus 26- week prednisone taper; PBO + Pred- 52 = placebo plus 52- week prednisone taper; TCZ- QW + Pred- 26 = tocilizumab once 
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APR levels. The overwhelming majority of TCZ- treated patients 
had low APR levels during disease flare. In the TCZ groups, 33 
of 36 first disease flares (91.7%) occurred with normal CRP levels 
(≤10 mg/liter) and 32 of 36 flares (88.9%) with normal ESR (<30 
mm/hour). In the PBO groups, APR levels remained normal at the 
time of first disease flares for approximately one- third of patients; 
of the 59 first disease flares, 20 (33.9%) were associated with nor-
mal CRP levels and 18 (30.5%) with normal ESRs.
Elevated APR levels without flare. More than half of the pa-
tients in the PBO groups had CRP elevations without disease 
flare during 1 year of follow- up (Table 1). Fifty- seven of the 101 
patients (56.4%) in the combined PBO groups had CRP level 
elevations (>10 mg/liter) during the 52- week follow- up period 
without disease flare (defined as CRP level or ESR elevated at 
2 consecutive visits between weeks 12 and 52 in the absence 
of clinical manifestations—beyond laboratory markers—of a dis-
ease flare). As anticipated, the CRP level was elevated in the ab-
sence of flare in only a minority of TCZ- treated patients: 5 (5.0%) 
in TCZ- QW + Pred- 26 and 3 (6.1%) in TCZ- Q2W + Pred- 26. 
Few patients in the TCZ groups had elevations of ESR that were 
not associated with disease flare: 2 patients (2.0%) in the TCZ- 
QW + Pred- 26 group and 3 patients (6.1%) in the TCZ- Q2W + 
Pred- 26 group. In contrast, more than half the patients in the 
PBO groups had elevations of ESR that were not reported as 
disease flares. Elevated CRP level and ESR in the absence of 
flare was observed in 40 patients (39.6%) in the PBO groups and 
3 patients (2.0%) in the TCZ groups (Table 1).
Remission. More than half of all patients (142 of 250; 56.8%) 
were in remission by the baseline visit because of glucocorticoids 
received during the 6- week screening period. Numerically higher 
proportions of patients in the TCZ groups than in the PBO groups 
achieved remission between baseline and week 12 (Figure  1A); 
this was observed for subgroups with newly diagnosed disease 
(Figure  1B) and relapsing disease (Figure  1C). Proportions of 
patients achieving remission increased from baseline to week 12 by 
28% in the TCZ- QW + Pred- 26 group and 23% in the TCZ- Q2W 
+ Pred- 26 group, compared with 2% in the PBO + Pred- 26 group 
and 14% in the PBO + Pred- 52 group. At week 12, the proportions 
of patients in remission were 66.0% (n = 33) in the PBO + Pred- 26 
group and 64.7% (n = 33) in the PBO + Pred- 52 group, compared 
with 83.0% (n = 83) in the TCZ- QW + Pred- 26 group (P = 0.10, ver-
sus PBO + Pred- 26; P = 0.03, versus PBO + Pred- 52). The propor-
tion of patients in remission in the TCZ- Q2W + Pred- 26 group was 
81.6% (n = 40), which was not significantly different from the PBO 
+ Pred- 26 group (P = 0.57) or the PBO + Pred- 52 group (P = 0.30).
Time to first flare according to starting prednisone 
dosage. Patients in the TCZ groups were more likely than those 
in the PBO groups to achieve sustained remission at each of the 
baseline prednisone dosages (Figure  2). Among patients who 
started at prednisone dosages of >30 mg/day, those in each of 
the TCZ groups experienced longer times to disease flares than 
those in either of the PBO + Pred groups (Figure  3A). Among 
patients who started at prednisone dosages of ≤30 mg/day, a 
divergence of the PBO + Pred- 26 group from the other 3 groups 
was evident from week 12, with a shorter time to flare in the PBO 
+ Pred- 26 group than the other groups (Figure 3B). In patients 
who started at prednisone dosages of ≤30 mg/day, the risk for 
flare was significantly lower among TCZ- treated patients than 
among PBO + Pred- 26–treated patients (HR 0.21 [99% CI 0.08–
0.54], P < 0.0001 for TCZ- QW + Pred- 26 and HR 0.28 [99% CI 
0.09–0.86], P = 0.0035 for TCZ- Q2W + Pred- 26). Among patients 
who started at prednisone dosages of ≤30 mg/day, the risk for 
flare did not differ between either of the TCZ groups and the PBO 
+ Pred- 52 group (HR 0.59 [99% CI 0.20–1.73], P = 0.2039 for 
TCZ- QW + Pred- 26 and HR 0.76 [99% CI 0.21–2.72], P = 0.5866 
for TCZ- Q2W + Pred- 26).
Figure 2. Sustained remission through week 52 according to baseline prednisone dosage. Percentages are based on number of patients 
receiving baseline dosage (*) and total number of patients in each treatment group at baseline (†). See Figure 1 for definitions. Color figure can 
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Methotrexate and sustained remission. Only 35 of 
250 patients (14%) received concomitant methotrexate (MTX) 
therapy during the study: 18 in the PBO groups and 17 in the TCZ 
groups (Table 2). One of the 18 patients (5.6%) receiving MTX in 
the combined PBO + Pred groups achieved sustained remission, 
compared with 15 of 83 patients (18.1%) who were not receiving 
MTX. Seven of 17 patients (41.2%) in the combined TCZ groups 
achieved sustained remission while receiving MTX, compared with 
75 of 132 patients (56.8%) who did not receive MTX.
DISCUSSION
The treatment of GCA has long been defined by glucocor-
ticoid treatment. Our analyses of glucocorticoid dosages and 
APR levels at disease flare provide new information about the 
natural history of GCA patients treated according to protocol 
with up to 1 year of prednisone. Given the importance of gluco-
corticoids in the management of GCA for the past 70 years and 
the fact that prolonged courses of glucocorticoid treatment have 
been the only treatment clearly known to be effective, it may 
seem remarkable that such information was not available earlier. 
Results from other trials with shorter prednisone tapers (12–14) 
and longitudinal studies using data from observational cohorts 
(15–17) have implied that the failure rate of glucocorticoid ther-
apy for GCA is high. However, GiACTA is the first randomized 
clinical trial to use a prednisone- tapering regimen in GCA for as 
long as 1 year, and the first trial in any disease to use a variable- 
dosage prednisone taper in which patients and investigators 
were blinded with regard to prednisone dosages. It therefore 
provides the most rigorous assessment to date of how well—or 
how poorly—glucocorticoids work in patients with GCA.
Equally important are the insights that these trial data provide 
into the contemporary management of GCA in the era of TCZ 
treatment. Three findings of major importance have resulted from 
Figure 3. Kaplan- Meier plot of time to first giant cell arteritis (GCA) flare according to starting prednisone dosage of >30 mg/day (A) and ≤30 
mg/day (B) in the intent- to- treat population. Patients never in remission were censored at day 1, and patients who withdrew from the study 
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this analysis, all of which have the potential to impact current treat-
ment strategies.
First, most disease flares observed in the GiACTA trial 
occurred while patients were still receiving prednisone and, in 
many cases, at dosages incompatible with long- term use. More 
than one- fifth of the 95 first disease flares that occurred in the 
GiACTA trial were observed in patients receiving >10 mg/day 
prednisone, and 72% occurred while patients were still receiving 
some dosage of prednisone. This finding is consistent with the fact 
that GCA patients have endured long courses of prednisone and 
experienced adverse effects of long- term glucocorticoid use as a 
nearly universal feature of their disease management, and with the 
concept of a lag time between loss of immunosuppressive control 
of GCA and clinical expression of disease flare. Although it was 
not formally addressed in this trial, MTX did not show benefits; 
the benefit of adjunctive MTX in GCA has previously been demon-
strated in a meta- analysis of 3 trials (18), but not with an effect size 
comparable to that of TCZ.
In the PBO + Pred groups, the slower (52- week) taper was 
associated with disease flare at higher dosages of prednisone in 
patients in the PBO + Pred- 52 group than in patients in the PBO + 
Pred- 26 group, who were more likely to reach a prednisone dos-
age of 0 mg/day before experiencing flare. These findings, which 
may appear counterintuitive, suggest that a lag exists between 
the reemergence of disease activity and the appearance of clinical 
manifestations. The data support the concept that subclinical dis-
ease activity begins in many patients as they taper to lower daily 
prednisone dosages, but that they do not experience symptoms 
until they have discontinued prednisone completely if the pred-
nisone taper is rapid (e.g., 26 weeks versus 52 weeks). Patients 
undergoing shorter prednisone tapers are therefore more likely 
to discontinue their prednisone entirely before the disease recur-
rence manifests as a clinical flare. In contrast, patients undergoing 
a slower prednisone taper may be more likely to experience clini-
cal disease flare while still receiving prednisone.
Second, APR levels are of little value in monitoring longitudi-
nal disease activity in patients treated with TCZ. CRP levels and 
ESRs remained low in nearly all TCZ- treated patients who experi-
enced disease flares. This is not surprising considering the antic-
ipated effects of IL- 6 inhibition on CRP concentrations and ESR. 
Our data also confirm that APR measurements have shortcom-
ings and the potential to mislead clinicians with regard to patients 
treated with prednisone alone. Although this point has been made 
by others (16,19), it remains underappreciated by many clinicians 
who manage patients with GCA. Approximately one- third of all 
disease flares in the PBO groups occurred while patients had 
normal CRP levels and ESRs (34% and 31%, respectively). Fur-
thermore, more than half of PBO- treated patients had elevations 
of either CRP level or ESR, and more than one- third had eleva-
tions of both APR levels without subsequent clinical disease flares 
(56.4%, 58.4%, and 39.6%, respectively).
These findings underscore the importance of the clinical 
assessment—particularly the importance of clinical experience 
and astute history- taking—in gauging whether GCA activity might 
be present. They also highlight the need for advances in the devel-
opment of clinically useful biomarkers and rigorous correlation 
between imaging study results and disease activity in longitudi-
nal disease assessments. It is possible that APR level elevations 
observed in the PBO- Pred groups that were not followed by 
disease flares during 52 weeks of follow- up indicate low- grade 
disease activity that remained subclinical (imaging studies were 
not performed on these patients). A discord between GCA clin-
Table 2. Methotrexate (MTX) use and sustained remission*
PBO +  
Pred- 26 
(n = 50)
PBO +  
Pred- 52 
(n = 51)
TCZ- QW + 
Pred- 26 
(n = 100)
TCZ- Q2W + 
Pred- 26 
(n = 49)
Received concomitant MTX 8 (16) 10 (20) 11 (11) 6 (12)
Did not receive concomitant 
MTX
42 (84) 41 (80) 89 (89) 43 (88)
MTX dosage, mean ± SD mg/
week
17.0 ± 6.0 15.4 ± 4.2 13.7 ± 3.1 13.1 ± 5.0
Total MTX dose during 52 
weeks, mean ± SD mg
663.1 ± 434.3 635.3 ± 414.7 577.1 ± 250.2 491.7 ± 376.4
Patients receiving MTX 
who achieved sustained 
remission†
0 (0) 1 (10) 4 (36) 3 (50)
Patients not receiving MTX 
who achieved sustained 
remission‡
7 (17) 8 (20) 52 (58) 23 (54)
* Except where indicated otherwise, values are the number (%) of patients in the corresponding treatment 
group. See Table 1 for definitions. 
† Percentage based on number of patients receiving MTX. 
‡ Percentage based on number of patients not receiving MTX. 
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ical symptoms and vascular changes detected by imaging has 
previously been described (20,21). The optimal imaging protocol 
in large vessel vasculitis in clinical practice is unclear, and the inter-
pretation of large vessel imaging studies in GCA is frequently not 
straightforward (22–24).
Third, these analyses demonstrate how swiftly the use of 
TCZ exerts a beneficial effect in GCA. The primary outcome 
measure of the trial was maintenance of remission at 52 weeks. 
However, our findings demonstrate that the effects of TCZ 
on induction of remission are rapid, which was most obvious 
in patients who experienced relapse (Figure  1C). In addition, 
even after 12 weeks, benefits of the combination of TCZ and 
prednisone over prednisone alone were apparent for the whole 
patient population (Figure  1A). These findings provide impor-
tant information about the timing of TCZ use. For clinicians to 
establish disease control as quickly as possible, avoid acute and 
chronic complications of poorly controlled disease, and prevent 
excessive side effects of glucocorticoid use, a treatment strategy 
that emphasizes initiation of TCZ treatment as early as possible, 
accompanied by the institution of aggressive prednisone tapers 
(perhaps even shorter than 6 months) may be appropriate. 
Longer- term follow- up of patients in the GiACTA trial will deter-
mine whether such a strategy has a durable effect in a substan-
tial number of patients, even after discontinuation of TCZ at 1 
year. The appropriateness of prednisone tapers more aggressive 
than those used in GiACTA cannot be routinely recommended 
until carefully conducted longitudinal studies and clinical trials 
are performed.
The addition of TCZ to glucocorticoid therapy enables 
faster glucocorticoid tapering than is possible for patients 
treated with glucocorticoids alone. Nevertheless, treatment with 
TCZ did not prevent disease flare in all patients. Nearly one- 
quarter of patients (24%) randomly assigned to either of the TCZ 
groups experienced ≥1 disease flare while receiving treatment. 
One potential contributor to the risk of disease flare in a subset 
of TCZ- treated patients is that Th1 cells, which are not directly 
affected by IL- 6 receptor blockade, may play an important role 
in some patients with GCA (25,26). Other explanations for dis-
ease recurrence despite ongoing IL- 6 receptor blockade must 
be examined in other studies. Nevertheless, the fact that GCA 
flares are possible in patients still taking TCZ underscores the 
argument that glucocorticoid tapering during GCA remission 
should continue to be carefully monitored to ensure patient 
safety and that clinicians must remain alert to the possibility of 
disease flare. Nevertheless, most patients treated with TCZ were 
able to discontinue glucocorticoids entirely, which is a highly 
desirable goal.
The data included in this analysis were from the largest 
randomized controlled trial of treatment for GCA conducted 
to date, which highlights the robustness of these findings. 
However, there are some limitations in these primarily post 
hoc exploratory analyses, including limited statistical testing. 
Flares were determined by investigators blinded with regard to 
CRP and informed only whether the ESR was higher or lower 
than 30 mm/hour. Although clinical descriptions were consis-
tent with typical symptoms of GCA flare, this approach in the 
setting of the randomized, double- blind, PBO- controlled trial 
might have led to a lower threshold for the diagnosis of some 
disease flares, out of concern for patient safety. The defini-
tion of remission without CRP that was used for the current 
analysis was not predefined per protocol except as part of 
a sensitivity analysis, but it allows for evaluation of remission 
outside the effect of TCZ on APR levels. Another limitation is 
the fact that clinical investigators were informed of clinically rel-
evant elevations in ESR in accordance with the dual- assessor 
approach previously described (8). However, only 9 patients 
had flares judged on the basis of ESR alone, and excluding 
these patients would only reduce the proportion of patients 
who experienced flare in the PBO + Pred- 26 group from 68% 
(34 of 50) to 64% (28 of 44). Finally, granular details of the 
clinical aspects of the disease flares were not collected, and 
future studies should aim to collect more detailed information.
In conclusion, these data provide important information 
about the efficacy of glucocorticoid treatment alone and about 
the occurrence of disease flares in the era of IL- 6 receptor 
blockade. The addition of TCZ to prednisone in the treatment 
of GCA allows more patients to achieve remission within the 
first few months of initiating treatment. This may be impor-
tant to prevent short- and long- term complications and reduce 
complications of long- term glucocorticoid use. Disease flares 
occur commonly in GCA, even when patients are receiving 
substantial dosages of prednisone and in patients treated with 
TCZ. Finally, APR levels have substantial limitations as indi-
cators of disease activity, both in patients treated with TCZ 
plus glucocorticoids and in those treated with glucocorticoids 
alone. Astute clinical assessment of patient symptoms and 
signs remains crucial in the longitudinal management of GCA. 
Greater emphasis on the identification of useful biomarkers 
and application of large vessel imaging studies to understand 
disease activity are important components of the research 
agenda for GCA.
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